InMode (INMD) FY Conference August 12, 2025 02:30 PM ET Speaker0Good afternoon, and thank you for joining us at this year's Canaccord Genuity growth conference. My name is Caitlin Cronin, and I'm one of the medical device analysts here at Canaccord Genuity. Joining us this afternoon is InMode, a leading player in the global energy based aesthetic treatments market. And with me today is Yair Malca, CFO. Before we begin, I want to remind everyone of any relevant disclosures which can be found on our conferenc ...

Financial Data and Key Metrics Changes - InMode generated revenues of $95.6 million in Q2 2025, compared to $86.4 million in Q2 2024, which excluded $16.2 million in preorders for new platforms not delivered by 2024 [7][8] - GAAP net income increased to $26.7 million, up 12% from $23.8 million in the previous year, while non-GAAP net income rose to $30.1 million from $29 million [11] - GAAP diluted earnings per share (EPS) for Q2 were $0.42, significantly up from $0.28 in 2024, and non-GAAP diluted EPS was $0.47, up from $0.34 [11] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 84% of total revenues in Q2 2025 [7] - Sales outside the U.S. reached $45 million, representing 48% of overall sales, marking an 11% year-over-year increase [8] - Sales and marketing expenses increased to $47.5 million from $45.1 million in the same period last year, reflecting continued investment in the sales team [9] Market Data and Key Metrics Changes - Europe was the largest geographical revenue contributor, achieving a record of $23 million [8] - The company has a direct sales force of over 297 representatives and distributor coverage in more than 74 countries [9] Company Strategy and Development Direction - The company is restructuring its sales team to enhance market penetration, particularly in the ophthalmology market with a specialized manager and dedicated sales team for the Envision platforms [5] - InMode is expanding its global footprint with new direct operations in Thailand and Argentina to improve customer support and streamline operations [5] - A user meeting is scheduled for late August to launch new wellness platforms aimed at increased blood circulation and pain relief for the urology community, with initial revenue expected in Q4 [6] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging medical aesthetic market, particularly in North America, due to reduced personnel spending and fewer treatments [4][5] - The company remains confident in its offerings and brand recognition, supported by a strong balance sheet and diversified portfolio [6] - Management expects revenues for 2025 to be between $365 million and $375 million, down from previous guidance of $395 million to $405 million [12][13] Other Important Information - Gross margin remained strong at 80% on a GAAP basis, consistent with Q2 2024, while non-GAAP gross margin was 80%, down from 81% [8][9] - The company generated $24 million in cash from operating activities during the quarter [11] - The impact of U.S. tariffs is expected to reduce gross margins by approximately 2% to 3% [12] Q&A Session Summary Question: Dynamics in Q1 and Q2 - Management noted that both Q1 and Q2 results were below expectations, with a slight weakness observed in both quarters [19][23] Question: Capital Purchases and Business Investment - Management indicated that there was no significant change in purchasing behavior between Q1 and Q2, with the market remaining challenging [23] Question: Capital Allocation and Share Repurchase - The company is considering additional share buybacks and remains open to various capital allocation options, but currently has no acquisitions planned [34] Question: Non-Invasive Procedure Growth - The increase in non-invasive procedures is attributed to customer behavior and the introduction of new platforms like Optimus Max [37] Question: Tariff Impact - The original tariff rate was reduced from 17% to 10% temporarily, with an expected annual impact of 2% to 3% on gross margins [63][66] Question: Urology Market and FDA Approval - The company is developing a platform for erectile dysfunction but is currently limited to pilot testing for blood circulation and pain relief until FDA approval is obtained [48][72] Question: Growth in International Markets - Management expressed confidence in the sustainability of growth in international markets, particularly in Europe, as the company expands its global presence [75]